Abzu reveals early predictive response biomarkers in first-ever clinically viable Myc oncogene inhibitor by Peptomyc®.

Stratifying patients at pretreatment by answering the question: Can we distinguish which patients will respond to OMO-103 treatment at baseline?

Peptomyc is focused on the development of a new generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.

Abzu reveals early predictive response biomarker in first-ever clinically viable Myc oncogene.

Your partner for precise and exceptional results.

We supported a small team of researchers with experience in Oncology and Health Biology. Our work not only resulted in a successful clinical trial and patented models to predict right-candidate enrollment for phase II clinical trials, but also earned Peptomyc a publication in Nature Medicine.

Abzu bioinformatician

A testament to innovation and collaboration.

Quote

Partnering with Abzu and using the QLattice increased our ability to really take advantage of all our clinical results to find unexpected and extremely valuable data that we could have missed otherwise.

Dr. Laura Soucek, CEO and co-founder

Revealing early predictive response biomarkers for clinical trials.

We identified response biomarkers in metastatic patients treated with the first-in-class Myc oncogene inhibitor.

Until Peptomyc’s successful clinical trial with OMO-103, Myc was thought to be undruggable. The Myc oncogene is persistently expressed in Burkitt lymphoma as well as many cervix, colon, breast, lung, pancreatic, and stomach cancers, making it one of the most sought-after drug targets in cancer.

Peptomyc used the QLattice and Abzu’s expertise in patient stratification to reveal early predictive response-biomarkers to treatment with OMO-103 in metastatic patients. The analysis by the QLattice was conducted on a very small clinical trial of 22 patients.

RNA Tx

This discovery made headlines.

Inside Precision Medicine
February 7, 2024

English

First MYC Inhibitor Shows Promise in Human Clinical Trial.

Nature Medicine
February 6, 2024

English

MYC targeting by OMO-103 in solid tumors: A phase 1 trial.

Yahoo! Finance
July 7, 2023

Danish

Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients.

Abzu
October 26, 2022

English

Abzu reveals insights in first-ever clinically viable Myc oncogene inhibitor by Peptomyc®.

Less data, more discovery.

Make the most out of every piece of information.

Contrary to the data-heavy demands of black-box AI, our technology thrives on minimal data. This efficiency not only accelerates the discovery process, but also reduces your barrier to entry to develop new, innovative drugs.

Share this case study.

What can you an Abzu do together?

A partnership protects your targets and designs, ensuring a swift and unobstructed path to market.

Through an exclusive agreement, Abzu guarantees a commitment to confidentiality, focus, and unparalleled innovation. Maximize your investment and results with a partnership in disease understanding or drug design.

Accelerate your R&D with best-in-class in silico solutions.

Read more case studies from Abzu in disease understanding and drug design.

Abzu’s QLattice uniquely identified key “partner” genes involved in skin spaceflight response, a new discovery for how spaceflight damages skin.
Understanding how bears can hibernate without developing blood clots or muscle atrophy can help humans prepare for the future of space travel.
A strategic partnership with Contera Pharma included ASO and siRNA therapeutic designs and target identification.

Subscribe for
notifications from Abzu.

You can opt out at any time. We’re cookieless, and our privacy policy is actually easy to read.